Cath Lab Digest - November 2007 - (Page 15)

15 • TRIUMPH REGISTRY. Translational research investigating underlying disparities in AMI patient’s health status. Primary Investigator: Aaron Kugelmass, MD Trials in Follow-Up: • AMIHOT II. A prospective, multi-center, randomized study of aqueous oxygen (AO) therapy for 90 minutes in anterior AMI patients with successful reperfusion (via PCI) < six hours after symptom onset. The objective of the study is to determine whether intracoronary perfusion of hyperoxemic blood in the AO therapy group immediately after successful PCI/ stenting for the treatment of acute myocardial infarction reduces the area of infarction (% left ventricle) as measured by T c99m Sestamibi SPECT imaging at 14 days post-PCI, with no worse than a six percent increase in the incidence of major adverse cardiac events. Primary Investigator: Aaron Kugelmass, MD • BARI 2 D. Bypass Angioplasty Revascularization Investigation in type 2 Diabetics. Primary Investigator: Adam Greenbaum, MD • ENDEAVOR III. Randomized, controlled trial of the Medtronic endeavor drug-eluting (ABT-578) coronary stent system versus the Cypher sirolimus-eluting coronary stent system in de novo native coronary artery lesions. Primary Investigator: Aaron Kugelmass, MD • ENDEAVOR IV. A randomized, controlled trial of the Medtronic Endeavor drugeluting (ABT-578) stent system versus the Taxus paclitaxel-eluting coronary stent system in de novo native coronary artery lesions. This study is investigating the utility of a new drug-eluting stent of the treatment of de novo or restenotic coronary artery lesions or vessels experiencing abrupt or threatened closure. Primary Investigator: Aaron Kugelmass, MD • TIMI-38. A comparison of CS-747 and clopidogrel in acute coronary syndrome subjects who are to undergo percutaneous coronary interventions. Primary Investigator: Aaron Kugelmass, MD • TAXUS-ATLAS. Treatment of de novo coronary disease using the TAXUS Liberte-SR paclitaxel-eluting stent. The purpose of this study is to evaluate the safety and efficacy of the TAXUS Liberte-SR stent in the treatment of de novo lesions compared with the TAXUS express paclitaxeleluting coronary stent system. Primary Investigator: Henry Kim, MD Procedure complete. Left to right: Francesco Caravello RN, Jeff Czentnar RN, Mohammad Arida MD, Leslie Breithaupt RN. Adam Greenbaum, MD Have you had any cath lab-related complications in the past year requiring emergent cardiac surgery? We have had one case in the past two years. What other modalities do you use to verify stenosis? Are you using physiology for lesion assessment? We primarily use FFR, fractional flow reserve, to determine stenosis severity in intermediate lesions. The PressureWire (Radi Medical Systems, Wilmington, MA) measures a gradient With advances in treatments for patients with congenital and acquired cardiac diseases, and rapid advances in noninvasive cardiac imaging such as CT and MRI angiography, I envision significant changes in both the types of patients and types of procedures performed in adult catheterization laboratories over the next decade. In diagnostic laboratories, I envision a shift toward more complex hemodynamic studies for survivors of congenital heart disease and those with complicated physiology, alongside a more streamlined approach to coronary angiography directed toward patients already selected for percutaneous revascularization. And, as percutaneous interventional technology and techniques advance, I envision a wider spectrum of less invasive and novel treatments for pathology such as long chronic total occlusions, valvular heart disease and heart failure, not previously imagined to ever be percutaneously approachable. — Adam Greenbaum, MD, Associate Director Cardiac Catheterization Lab

Table of Contents Feed for the Digital Edition of Cath Lab Digest - November 2007

Henry Ford Heart and Vascular Institute Treating Patients with Complex Vascular Disease with a Multi-Disciplinary Approach Improving Patient Compliance with Antiplatelet Medications Clinical Editor’s Corner Cath Lab Nurse/Tech Vascular Access and Closure Using the StarClose® Device The Clinical and Economic Impact of Measuring Fractional Flow Reserve FFR and Choosing an Optimal Revascularization Strategy Finally! The New Registered Cardiac Electrophysiology Specialist (RCES) Credential Use of a Mobile Lab to ‘Test the Waters’ at a Rural Hospital Remembering a Cardiac Cath Lab History ACVP• Membership Page What Do You Think? The Ten-Minute Interview with… Ernie Livingston, RN, BSN SICP* Chapter Updates Who’s in Charge? Working to Eliminate Bottlenecks: Florida Hospital’s Cardiac Cath Lab Achieves Greater Efficiency and Higher Satisfaction Preserving Left Ventricular Function during Percutaneous Coronary Intervention Ask the Clinical Instructor: A Q&A Column for Those New to the Cath Lab Making the Most of Your First Impression: Interviewing Tips and Techniques CEU Education Center Clinical & Industry News Meetings Calendar

Cath Lab Digest - November 2007

For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.